ProMIS Neurosciences Ownership
| PMN Stock | USD 0.92 0.11 10.68% |
Shares in Circulation | First Issued 2005-06-30 | Previous Quarter 19.8 M | Current Value 30.1 M | Avarage Shares Outstanding 3.8 M | Quarterly Volatility 5.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
ProMIS |
ProMIS Stock Ownership Analysis
About 45.0% of the company outstanding shares are owned by corporate insiders. The book value of ProMIS Neurosciences was at this time reported as 0.2. The company had not issued any dividends in recent years. ProMIS Neurosciences had 1:60 split on the 28th of June 2022. ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimers disease , amyotrophic lateral sclerosis , and multiple system atrophy in Canada. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada. Promis Neurosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 5 people. To find out more about ProMIS Neurosciences contact the company at 416 847 6898 or learn more at https://www.promisneurosciences.com.Besides selling stocks to institutional investors, ProMIS Neurosciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different ProMIS Neurosciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align ProMIS Neurosciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
ProMIS Neurosciences Quarterly Liabilities And Stockholders Equity |
|
About 45.0% of ProMIS Neurosciences are currently held by insiders. Unlike ProMIS Neurosciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against ProMIS Neurosciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of ProMIS Neurosciences' insider trades
ProMIS Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ProMIS Neurosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ProMIS Neurosciences backward and forwards among themselves. ProMIS Neurosciences' institutional investor refers to the entity that pools money to purchase ProMIS Neurosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Sandy Spring Bank | 2024-06-30 | 3.3 K | Bank Of America Corp | 2024-06-30 | 1.7 K | Royal Bank Of Canada | 2024-06-30 | 713 | Td Waterhouse Canada Inc | 2024-06-30 | 133 | Wells Fargo & Co | 2024-06-30 | 20.0 | Northwestern Mutual Wealth Management Co | 2024-06-30 | 4.0 | Jpmorgan Chase & Co | 2024-06-30 | 3.0 | Ubs Group Ag | 2024-06-30 | 0.0 | Northeast Financial Consultants, Inc | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 2.7 M | Sphera Funds Management Ltd. | 2024-09-30 | 1.9 M |
ProMIS Neurosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ProMIS Neurosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on ProMIS Neurosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ProMIS Neurosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pair Trading with ProMIS Neurosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ProMIS Neurosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProMIS Neurosciences will appreciate offsetting losses from the drop in the long position's value.Moving together with ProMIS Stock
| 0.72 | ME | 23Andme Holding | PairCorr |
| 0.75 | VALN | Valneva SE ADR | PairCorr |
| 0.62 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
Moving against ProMIS Stock
| 0.79 | KZR | Kezar Life Sciences | PairCorr |
| 0.65 | MLYS | Mineralys Therapeutics, | PairCorr |
| 0.31 | MDGL | Madrigal Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to ProMIS Neurosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ProMIS Neurosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ProMIS Neurosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ProMIS Neurosciences to buy it.
The correlation of ProMIS Neurosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ProMIS Neurosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ProMIS Neurosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ProMIS Neurosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProMIS Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProMIS Neurosciences. If investors know ProMIS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProMIS Neurosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.04 | Revenue Per Share 0.001 | Return On Assets (4.81) | Return On Equity (10.99) |
The market value of ProMIS Neurosciences is measured differently than its book value, which is the value of ProMIS that is recorded on the company's balance sheet. Investors also form their own opinion of ProMIS Neurosciences' value that differs from its market value or its book value, called intrinsic value, which is ProMIS Neurosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProMIS Neurosciences' market value can be influenced by many factors that don't directly affect ProMIS Neurosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProMIS Neurosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProMIS Neurosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProMIS Neurosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.